CHICAGO, June 20, 2017 /PRNewswire/ -- Schulman IRB, the industry-leading central IRB in customer service and technology, will preview its new Central Neurology Review (CNR) service today at the Drug Information Association (DIA) Annual Meeting in Chicago, IL. DIA attendees will receive an exclusive first look at the therapeutically specialized service, developed through an alliance between Schulman and the National Biomedical Research Ethics Council (NBREC), a Nevada-based 501(c) non-profit. Schulman staff and a representative from NBREC will be at booth 816 to discuss CNR with attendees.
CNR is a specialized independent IRB and scientific review committee (SRC) designed to help research institutions and biopharma and device companies navigate the latest developments in neurology research and human subject protections.
With the added SRC review service, CNR can provide early identification of potential areas for study design improvement, potentially minimizing study delays and the need for costly protocol amendments. Committee members include researchers and industry leaders experienced the latest techniques, methodologies and discoveries in neurology research.
"We are excited to share this exclusive sneak peek with the DIA community and get their feedback on the service," said Eli Alford, COO at Schulman IRB. "DIA brings together some of the top minds in clinical research, so it seemed a great opportunity to give them a first glimpse of the service and discuss how we can improve the pathway to new neurological disease interventions."
CNR will officially launch in July 2017.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services in clinical quality assurance (CQA) and human research protections (HRP), and it offers a commercial institutional biosafety committee (IBC) service. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
Established in 2012 as a Nevada-based 501(c)(3) not-for-profit organization, the National Biomedical Research Ethics Council (NBREC) is committed to the goals of assuring individual research volunteer safety through the expanded use of single ethics committees, expanding international awareness for research ethics and improving population public health efforts allied with disease surveillance and control.
For more information, please visit http://nbrec.org/.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/schulman-irb-to-preview-new-central-neurology-review-service-at-drug-information-association-dia-annual-meeting-300476130.html
SOURCE Schulman IRB